The clinical implementation of exosomes for cancer screening and disease response or relapse prediction demands new facile methods for serum detection and quantification of TEX. The main scope of this project is to create a nano- platform based on a new class of magnetoplasmonic nanoparticles capable to selectively detect, bind and isolate acute myeloid leukemia-derived exosomes from blood samples using aptamer mediated recognition of tumor specific antigens (CD 117) for the modern management of cancer in the era of personalized medicine.
Multifunctional magnetoplasmonic nanomaterials
Magneto/plasmonic nanoparticles
Aptamers are single-stranded oligonucleotides (DNA or RNA ) with specific three-dimensional conformation that can bind targets with high affinity and specificity. The main advantages of aptamers over antibodies is their small size, facile chemical synthesis and lack of imune response. The gold plasmonic shell on top of the magnetic core allows a better functionalization of the nanoparticles with -SH modified aptamers while the magnetic core enables magnetic field mediated isolation of TEX from blood samples. The aproach has a high degree of novelty due to the use of magneto/plasmonic nanoparticles for TEX isolation and due to the use of aptamer mediated recognition of myeloid leukemia specific antigens (CD 117) present in the exosomal membrane. The validation of the concept will be done using different controlled mixtures of exosomes for set-up calibration, follewed by tests in the clinical setting using AML pacients derived blood samples.
Project ID:
PN-III-P4-ID-PCCF-2016-0112Project Acronym: NanoTEX